Fixed-Duration Ibrutinib-Venetoclax Promising in First-Line CLL

(MedPage Today) -- A fixed-duration, first-line combination of ibrutinib (Imbruvica) plus venetoclax (Venclexta) appeared feasible for chronic lymphocytic leukemia (CLL) patients who achieved undetectable minimal residual disease (MRD) status...